A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

NCT00993044 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Refractory Solid Tumors in Children

Interventions

DRUG: Irinotecan
DRUG: Vincristine
DRUG: Temozolomide
DRUG: Bevacizumab

Sponsor

Children's Hospital Los Angeles